Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Assets Average (2016 - 2025)

Neurocrine Biosciences' Assets Average history spans 15 years, with the latest figure at $4.4 billion for Q4 2025.

  • For Q4 2025, Assets Average rose 22.66% year-over-year to $4.4 billion; the TTM value through Dec 2025 reached $4.4 billion, up 22.66%, while the annual FY2025 figure was $4.2 billion, 19.8% up from the prior year.
  • Assets Average reached $4.4 billion in Q4 2025 per NBIX's latest filing, up from $4.1 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $4.4 billion in Q4 2025 to a low of $1.8 billion in Q1 2021.
  • Average Assets Average over 5 years is $2.8 billion, with a median of $2.6 billion recorded in 2023.
  • Peak YoY movement for Assets Average: grew 4.41% in 2022, then skyrocketed 42.2% in 2024.
  • A 5-year view of Assets Average shows it stood at $2.0 billion in 2021, then rose by 10.33% to $2.3 billion in 2022, then surged by 35.18% to $3.0 billion in 2023, then rose by 18.92% to $3.6 billion in 2024, then grew by 22.66% to $4.4 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Assets Average are $4.4 billion (Q4 2025), $4.1 billion (Q3 2025), and $3.8 billion (Q2 2025).